Sarah Cannon, the Cancer Institute of Hospital Corporation of America (HCA), today announced that Genospace, LLC, a cloud-based software company focused on advancing personalized medicine, will merge with its organization and become a wholly-owned subsidiary. By joining forces, Sarah Cannon and Genospace will harness and use molecular profiling data to more effectively match cancer patients to cutting-edge therapies in clinical trials.
Sarah Cannon and Genospace, LLC Announce Merger to Enhance Cancer Care Through Personalized Medicine Platform
Human Longevity, Inc. Launches the Health Nucleus, a Comprehensive and Personalized Health Platform for Individuals
Human Longevity, Inc. (HLI), the genomics-based, technology-driven company working to revolutionize the practice of medicine, announced today the launch of the company’s first Health Nucleus™, a genomic powered clinical research project that has the potential to transform healthcare. The inaugural Health Nucleus is located in San Diego, CA, at HLI’s headquarters facility. More Health Nucleus facilities are slated to open in 2016 in other US and International cities.
BC Platforms Launches Personalized Precision Medicine Initiative With the University of Colorado Anschutz Medical Campus
BC Platforms, a world leader in genomic data management solutions, today announced that the University of Colorado Anschutz Medical Campus will use the company’s world-leading, comprehensive data management program to support the launch of the university’s new personalized medicine initiative aiming at translating community genomics into individual well-being.
Berg, a Boston-based biopharmaceutical company at the forefront of precision medicine, today announced it will join an industry collaboration with Genomics England. Formed by U.K. Prime Minister David Cameron, Genomics England is partnering with innovative health companies like Berg to accomplish its mission to sequence 100,000 human genomes and create a new genomic medicine service for the National Health Services (NHS) by 2017. The project focuses on patients with rare diseases and six common cancers.
Earlier this year MediSapiens announced a joint venture with International Cancer Advocacy Network (ICAN) to develop and publish Remission Coach®, a web-based solution that addresses the urgency of cancer management. This innovative solution provides cancer patients with a personalized platform for actively determine the most appropriate clinical trial for that patient’s disease and treatment history. Now MediSapiens announces collaboration with Genoscoper Laboratories, leading animal DNA diagnostics laboratory.